Fredag 27 December | 04:01:30 Europe / Stockholm

Prenumeration

2022-01-25 10:00:00

BioInvent, the first company to discover two innovative new cancer antibody targets, is fully funded to develop antibodies across five clinical projects over the coming three to four years. Being a biotech company with a large war chest makes this an investment for biotech and more risk-averse investors alike.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/